Patent Expense Reimbursement. Sponsor shall reimburse UGARF for all of UGARF’s actual expenses incurred in filing for, prosecuting, and maintaining any and all UGARF Intellectual Property and Joint Intellectual Property (“Patent Expenses”). However, notwithstanding the foregoing, Sponsor is not required to reimburse UGARF for Patent Expenses incurred with respect to specific UGARF Intellectual Property rights and UGARF’s interest in specific Joint Intellectual Property rights if Sponsor affirmatively and by written notice to UGARF declines to license those rights. In that case, effective as of receipt of Sponsor’s notice or upon a later effective date stated in the notice, the declined rights shall be removed from the scope of any License Agreement, Sponsor shall no longer have any obligation to reimburse UGARF for associated Patent Expenses thereafter incurred, and UGARF thereafter shall have no obligation to Sponsor whatsoever with respect to such declined rights.
Patent Expense Reimbursement. Licensee shall reimburse UGARF for all Licensed Patent Expenses. However, notwithstanding the foregoing, Licensee is not required to reimburse UGARF for Licensed Patent Expenses incurred with respect to specific Licensed Patents if Licensee affirmatively and by written notice to UGARF declines to license those rights. In that case, effective as of receipt of Licensee’s notice or upon a later effective date stated in the notice, the declined rights shall be removed from the scope of any license granted herein (or in any Sublicense) and from the definition of Licensed Patents; Licensee shall no longer have any obligation to reimburse UGARF for the associated Licensed Patent Expenses thereafter incurred; and UGARF thereafter shall have no obligation to Licensee or Sublicensee whatsoever with respect to such declined rights, which UGARF may license to one or more other entities in UGARF’s discretion.
Patent Expense Reimbursement. The patent expense reimbursement under Paragraph 3.7 is: [***] *** Certain information in this agreement has been omitted and filed separately with the Securities and Exchange Commission. [***] indicates that text has been omitted and is the subject of a confidential treatment request. FINAL EXHIBIT B [***] REPORT UNDER PARAGRAPH 5.1(b) FOR LICENSE AGREEMENT A30817 BETWEEN ALLAKOS INC. AND THE XXXXX XXXXXXX UNIVERSITY EFFECTIVE DATE [***] This report format is to be used to report [***] to JHU. [***]. *** Certain information in this agreement has been omitted and filed separately with the Securities and Exchange Commission. [***] indicates that text has been omitted and is the subject of a confidential treatment request. FINAL EXHIBIT C PATENT RIGHTS UNDER PARAGRAPH 1.14 [***] *** Certain information in this agreement has been omitted and filed separately with the Securities and Exchange Commission. [***] indicates that text has been omitted and is the subject of a confidential treatment request. FINAL CONFIDENTIAL EXHIBIT D BIOLOGICAL MATERIAL(S) UNDER PARAGRAPH 1.2 [***] *** Certain information in this agreement has been omitted and filed separately with the Securities and Exchange Commission. [***] indicates that text has been omitted and is the subject of a confidential treatment request. FINAL EXHIBIT E [***] UNDER PARAGRAPH 3.7 [***] *** Certain information in this agreement has been omitted and filed separately with the Securities and Exchange Commission. [***] indicates that text has been omitted and is the subject of a confidential treatment request. FINAL CONFIDENTIAL EXHIBIT F FORM OF STOCK ISSUANCE AGREEMENT UNDER PARAGRAPH 3.8 (see attached) FINAL ALLAKOS INC. COMMON STOCK ISSUANCE AGREEMENT This Common Stock Issuance Agreement (the “Agreement”) is made as of , 2013, by and between Allakos Inc., a Delaware corporation (the “Company”), and The Xxxxx Xxxxxxx University (the “JHU”).
Patent Expense Reimbursement. (i) Company shall reimburse Hadasit in the amount of twelve thousand two hundred New Israeli Shekels (NIS 12,200), on account of all previous documented patent expenses and costs incurred by Hadasit in connection with the Licensed Patents and not reimbursed by a third party prior to the Effective Date, within fourteen (14) days of the Effective Date. The balance, which shall be advised to the Company on or around the Effective Date, shall be due and payable by the Company to Hadasit six (6) months of the Effective Date; and (ii) Company shall reimburse RDC for previous documented patent expenses and costs incurred by HKUST or RDC in connection with the Licensed Patents and not reimbursed by a third party prior to the Effective Date, in the amount of one hundred and thirteen thousand US Dollars (US Dollars 113,000) as follows: Twelve Thousand US Dollars (US$12,000) within fourteen (14) days of the Effective Date, and the balance which shall be advised to the Company on or around the Effective Date, in two (2) equal instalments, the first to be made one (1) year of the Effective Date, and the second to be made two (2) years of the Effective Date. Notwithstanding any provisions of this Agreement, the Company shall reimburse the patent expenses incurred by HKUST or RDC directly to RDC by wire transfer.
Patent Expense Reimbursement. Reimbursement of all Patent Expenses incurred prior to the Effective Date, plus the first $5,000 in Patent Expenses incurred on or after the Effective Date, will be deferred until the earlier of (a) the closing of Subsequent Equity Financings aggregating $2 Million or (b) the second anniversary of Effective Date. With respect to any Patent Expenses incurred on or after the Effective Date that are not deferred, Company will reimburse Cornell as incurred. For any startup company that elects to locate its principal operations in Xxxxxxxx County, NY, Cornell will increase the $5,000 deferral to $20,000 and extend the second anniversary of the Effective Date to the third anniversary. All payments will be due within 30 days following the date an itemized invoice is sent from Cornell to Company. Past Patent Costs as of the Effective Date are approximately $ . Item Q. Patent Rights: CORNELL REFERENCE TITLE COUNTRY APPLICATION NUMBER PATENT NUMBER STATUS Item R. Copyrights (includes and the following applications and/or registrations, if any, and any unregistered copyrights in the Works): CORNELL REFERENCE NAME COUNTRY APPLICATION NUMBER REGISTRATION NUMBER STATUS Item S. Technical Information (if applicable, and may be described further in an appendix):
Patent Expense Reimbursement. Reimbursement of all past Patent Expenses, plus the first $5,000 in future Patent Expenses, will be deferred until the earlier of (a) the closing of Subsequent Equity Financings aggregating $2 Million or (b) the second anniversary of Effective Date. With respect to any future Patent Expenses that are not deferred, Company will reimburse Cornell as incurred. For any startup companies that elect to locate their principal operations in Xxxxxxxxx County, NY, Cornell will increase the $5,000 to $20,000 and extend the second anniversary to the third anniversary. Item P. Patent Rights: CORNELL REFERENCE TITLE COUNTRY APPLICATION NUMBER PATENT NUMBER STATUS Item Q. Technical Information (if applicable, and may be described further in an appendix): 1.
Patent Expense Reimbursement. As additional consideration for the license granted in this Agreement, LICENSEE must reimburse SYSTEM for its documented expenses incurred in the prosecution and maintenance of PATENT RIGHTS in the TERRITORY, as further described in Article VI.
Patent Expense Reimbursement. As additional consideration for the license granted herein, INHIBITEX shall reimburse SYSTEM for its documented expenses incurred after the EFFECTIVE DATE in the prosecution and maintenance of the PATENT RIGHTS as further described in Article VI. Reimbursement of SYSTEM documented expenses shall be provided by INHIBITEX to SYSTEM no later than thirty (30) days following INHIBITEX's receipt of SYSTEM's statement of expenses.
Patent Expense Reimbursement. To the extent that expenses incurred by Xxxxxx Estate or Xxxxxx Xxxxxx II since the death of Xxxxxx Xxxxxx I for the foreign filing, prosecution, maintenance and revival of Transferred Listed Patents have exceeded five thousand dollars ($5,000), then within thirty (30) days after receiving an invoice from Xxxxxx Estate itemizing the costs and the date they were incurred, Assignee shall reimburse to Xxxxxx Estate such costs up to a maximum of five thousand dollars ($5,000) (such that the total recovered costs ***Text Omitted and Filed Separately Confidential Treatment Requested Under 17 C.F.R. §§ 200.80(b)(4) and 240.24b-2 are the five thousand dollars ($5,000) of the first payment under Section 4.1(a), plus the up to five thousand dollars ($5,000) under this Section 4.1(c)). Xxxxxx Estate shall provide its invoice under this Section no later than sixty (60) days after the Effective Date. To avoid doubt, the reimburseable expenses under this Section are patent filing, prosecution, maintenance and revival expenses, not probate-related or transactional expenses.
Patent Expense Reimbursement. Licensee agrees to reimburse University for documented Patent Rights patent costs incurred by University for the preparation, filing, prosecution, issuance, and maintenance of Patent Rights patents. University shall furnish copies to Licensee of the legal billing invoices or statements received by the University from outside patent counsel for all such Patent Rights patent costs for which University seeks reimbursement from Licensee hereunder. Licensee shall forward payment checks for reimbursement of patent costs to University at University’s notice address (Section 17) within thirty (30) days following the date of Licensee’s receipt of copies of the billing invoices for such patent costs from University.
